EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Waning of first- and second-dose ChAdOx1 and BNT162b2 COVID-19 vaccinations: a pooled target trial study of 12.9 million individuals in England, Northern Ireland, Scotland and Wales

Steven Kerr, Stuart Bedston, Declan T Bradley, Mark Joy, Emily Lowthian iD, Rachel M Mulholland, Ashley Akbari iD, F D Richard Hobbs, Srinivasa Vittal Katikireddi iD, Simon de Lusignan iD, Igor Rudan, Fatemeh Torabi und 4 weitere

International Journal of Epidemiology · 2023

DOI: 10.1093/ije/dyac199 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Epidemiology, 2023. Verfasst von Steven Kerr und 15 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Medical Informatics, Usher Institute, The University of Edinburgh, Edinburgh, UK. Hauptthemen laut MEDLINE: COVID-19, Smallpox Vaccine. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Department of Health, British Heart Foundation, Chief Scientist Office.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Several SARS-CoV-2 vaccines have been shown to provide protection against COVID-19 hospitalization and death. However, some evidence suggests that notable waning in effectiveness against these outcomes occurs within months of vaccination. We undertook a pooled analysis across the four nations of the UK to investigate waning in vaccine effectiveness (VE) and relative vaccine effectiveness (rVE) against severe COVID-19 outcomes.

Methods

We carried out a target trial design for first/second doses of ChAdOx1(Oxford–AstraZeneca) and BNT162b2 (Pfizer–BioNTech) with a composite outcome of COVID-19 hospitalization or death over the period 8 December 2020 to 30 June 2021. Exposure groups were matched by age, local authority area and propensity for vaccination. We pooled event counts across the four UK nations.

Results

For Doses 1 and 2 of ChAdOx1 and Dose 1 of BNT162b2, VE/rVE reached zero by approximately Days 60–80 and then went negative. By Day 70, VE/rVE was –25% (95% CI: –80 to 14) and 10% (95% CI: –32 to 39) for Doses 1 and 2 of ChAdOx1, respectively, and 42% (95% CI: 9 to 64) and 53% (95% CI: 26 to 70) for Doses 1 and 2 of BNT162b2, respectively. rVE for Dose 2 of BNT162b2 remained above zero throughout and reached 46% (95% CI: 13 to 67) after 98 days of follow-up.

Conclusions

We found strong evidence of waning in VE/rVE for Doses 1 and 2 of ChAdOx1, as well as Dose 1 of BNT162b2. This evidence may be used to inform policies on timings of additional doses of vaccine.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Smallpox VaccineHumansBNT162 VaccineCOVID-19 VaccinesNorthern IrelandWalesSARS-CoV-2VaccinationEnglandScotland

Stichwörter der Autor:innen

COVID-19vaccine effectivenessvaccine waning

Substanzen

BNT162 VaccineCOVID-19 VaccinesSmallpox Vaccine

Autor:innen und Institutionen

  • Centre for Medical Informatics, Usher Institute, The University of Edinburgh, Edinburgh, UK.
  • Population Data Science, Swansea University Medical School, Swansea University, Swansea, UK.
  • School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK.
  • Public Health Agency, Belfast, UK.
  • Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
  • Department of Education and Childhood Studies, Swansea University, Swansea, UK.

ORCID-Profile: Emily Lowthian, Ashley Akbari, Srinivasa Vittal Katikireddi, Simon de Lusignan

Förderung

  • Department of Health
  • British Heart Foundation
  • Chief Scientist Office
  • Medical Research Council
  • Wellcome Trust
  • Data and Connectivity National Core Study
  • Health Data Research UK
  • Office for National Statistics

Zitieren

APA

Kerr, S., Bedston, S., Bradley, D. T., Joy, M., Lowthian, E., Mulholland, R. M., Akbari, A., Hobbs, F. D. R., Katikireddi, S. V., de Lusignan, S., Rudan, I., Torabi, F., Tsang, R. S. M., Lyons, R. A., Robertson, C., & Sheikh, A. (2023). Waning of first- and second-dose ChAdOx1 and BNT162b2 COVID-19 vaccinations: a pooled target trial study of 12.9 million individuals in England, Northern Ireland, Scotland and Wales. International Journal of Epidemiology. https://doi.org/10.1093/ije/dyac199

Vancouver

Kerr S, Bedston S, Bradley DT, Joy M, Lowthian E, Mulholland RM, et al. Waning of first- and second-dose ChAdOx1 and BNT162b2 COVID-19 vaccinations: a pooled target trial study of 12.9 million individuals in England, Northern Ireland, Scotland and Wales. International Journal of Epidemiology. 2023. doi:10.1093/ije/dyac199

BibTeX
@article{Kerr2023,
  author = {Kerr, Steven and Bedston, Stuart and Bradley, Declan T and Joy, Mark and Lowthian, Emily and Mulholland, Rachel M and Akbari, Ashley and Hobbs, F D Richard and Katikireddi, Srinivasa Vittal and de Lusignan, Simon and Rudan, Igor and Torabi, Fatemeh and Tsang, Ruby S M and Lyons, Ronan A and Robertson, Chris and Sheikh, Aziz},
  title = {Waning of first- and second-dose ChAdOx1 and BNT162b2 COVID-19 vaccinations: a pooled target trial study of 12.9 million individuals in England, Northern Ireland, Scotland and Wales},
  journal = {International Journal of Epidemiology},
  year = {2023},
  doi = {10.1093/ije/dyac199}
}
Kostenlos starten →